Abstracts tagged "skin"

Abstract Number: 1172 • ACR Convergence 2020
Cardiovascular involvement as a clue for diagnosis of Juvenile Systemic Sclerosis sine scleroderma
Gloria Lanzoni¹, Giorgia Martini¹, Alessandra Meneghel¹, Fabio Vittadello², Biagio Castaldi¹, Elisabetta Zanatta³ and Francesco Zulian¹, ¹Department of Woman's and Child's Health, University of Padova, Padua, Italy, ²Centro Studi Statistici Explora, Padua, Italy, ³Department of Medicine-DIMED, University of Padova, Padua, Italy
Background/Purpose: Juvenile Systemic Sclerosis (JSSc) is a rare condition in childhood and its variety with no skin involvement, systemic sclerosis sine scleroderma (JSSSS) is anecdotal…
Abstract Number: 1373 • ACR Convergence 2020
IL-23 Skin and Joint Profiling in Psoriatic Arthritis: Novel Perspectives in Understanding Clinical Responses to IL-23 Inhibitors
Alessandra Nerviani¹, Marie-Astrid Boutet¹, Wang Sin Gina Tan¹, Katriona Goldmann¹, Nirupam Purkayastha¹, Tamas Lajtos¹, Rebecca Hands¹, Myles Lewis¹, Stephen Kelly² and Costantino Pitzalis³, ¹Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, London, United Kingdom, ²Mile End Hospital, Barts Health NHS Trust, London, United Kingdom, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: PsA is a chronic heterogeneous inflammatory condition affecting up to 30% of patients with skin and/or nail psoriasis and the IL-23/IL-17 axis is believed…
Abstract Number: 1397 • ACR Convergence 2020
Clinical and Demographic Features of Morphea Patients with Mucocutaneous Involvement: A Cross Sectional Study from the Morphea of Adults and Children Cohort
Smriti Prasad¹, Samantha Black², Shivani Sharma³ and Heidi Jacobe¹, ¹University of Texas Southwestern Medical Center, Dallas, TX, ²The University of Texas Southwestern Medical Center, Dallas, TX, ³University of Texas Southwestern, Dallas, TX
Background/Purpose: Morphea is an autoimmune skin condition that produces skin and soft tissue sclerosis. While clinical manifestations of morphea have been well-described, mucocutaneous findings such…
Abstract Number: 1610 • ACR Convergence 2020
Cutaneous Side Effects of Hydroxychloroquine in Rheumatic Diseases –Combination of “Traditional” Multivariate Analysis for Risk Factors AndClassification Model Development Using Supervised Machine Learning –Single Centre Retrospective Cohort Study in India
Sandeep Surendran¹, Mithun CB¹, Arun Tiwari², Vishal Marwaha¹ and Sekhar Easwar¹, ¹Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, Kerala, India, ²Amrita Institute of Medical Sciences, Kochi, Kerala, India., Kochi, India
Background/Purpose: Hydroxychloroquine (HCQ) is associated with varied cutaneous side effects but only few studies in literature characterizing the risk factors for this. Recently machine learning…
Abstract Number: 0076 • ACR Convergence 2020
The Role of Interferon Kappa in Psoriasis
Mehrnaz Gharaee-Kermani¹, Shannon Estadt², Sonya Wolf-Fortune¹, Jianhua Liu¹, Tamra Reed³, Johann Gudjonsson⁴ and J. Michelle Kahlenberg⁵, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Ypsilanti, MI, ³University of Michigan, Ann Arbor, ⁴University of Michigan, Ann ArborUniversity of Michigan, ⁵Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Psoriasis is a common, chronic inflammatory autoimmune skin diseases characterized by hyperproliferation and abnormal differentiation of keratinocytes and infiltration of inflammatory cells. Early infiltration…
Abstract Number: 1631 • ACR Convergence 2020
No Increased Risk of Liver Dysfunction from Tildrakizumab Treatment: Post Hoc Analyses of the Tildrakizumab Psoriasis Clinical Program
Mark Lebwohl¹, Darren West², Alan Mendelsohn³, Stephen Rozzo³ and Giampiero Girolomoni⁴, ¹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, ²Spectrum Dermatology, Scottsdale, AZ, ³Sun Pharmaceutical Industries, Inc., Princeton, NJ, ⁴Section of Dermatology, Department of Medicine, University of Verona, Verona, Italy
Background/Purpose: Tildrakizumab (TIL) is a high‐affinity, humanized, immunoglobulin G1κ, anti–interleukin-23p19 monoclonal antibody approved for the treatment of moderate to severe plaque psoriasis. We evaluated adverse…
Abstract Number: 0263 • ACR Convergence 2020
Factors Associated with Disease Activity Remission and Recurrence in Cutaneous Lupus Erythematosus
Stephanie Florez-Pollack¹, Syed Rizvi², Benjamin Chong² and Linda Hynan², ¹University of Pennsylvania, PHILADELPHIA, PA, ²University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Cutaneous lupus erythematosus (CLE) is a photosensitive skin disorder that can occur with systemic lupus erythematosus. As CLE often fluctuates in disease activity, little…
Abstract Number: 1802 • ACR Convergence 2020
Vitamin D Level: Predictor of SLE Disease Activity in AA Cohort with CLE?
Ileannette Robledo-Vega¹, John Scheinuk², Emmanuel Pardo², Ansley Pratt², Soham Mahato³, Andrew G. Chapple² and Myriam Guevara⁴, ¹Louisiana State University Health Sciences Center, New Orlenas, LA, ²Louisiana State University, New Orleans, LA, ³LSUHSC School of Public Health, New Orleans, LA, ⁴Lousiana State University Health Sciences Center, New Orleans, LA
Background/Purpose: There are few predominant African American (AA) epidemiological studies in Cutaneous Lupus Erythematosus (CLE). The Gilliam classification divides CLE into lupus specific, acute cutaneous…
Abstract Number: 2693 • 2018 ACR/ARHP Annual Meeting
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
Brigit Kersten, Nathan den Broeder, Frank van den Hoogen, Els van den Ende and Madelon Vonk, Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Patients with systemic sclerosis who have proximal skin involvement are classified as diffuse cutaneous systemic sclerosis (DcSSc). Patients with progressive skin involvement have worse prognosis.…
Abstract Number: 2716 • 2018 ACR/ARHP Annual Meeting
A New Score to Predict Digital Ulcers Combining Clinical Data, Imaging and Patient History in Systemic Sclerosis
Stefanie Friedrich^1,2, Susanne Lueders³, Gerd R. Burmester⁴, Gabriela Riemekasten⁵ and Sarah Ohrndorf⁴, ¹Department of of Rheumatology and Clinical Immunology, Charité University Hospital, Berlin; Germany, Berlin, Germany, ²Department of Radiology, Charité University Hospital, Berlin; Germany, Berlin, Germany, ³Department of Gastroenterology and Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ⁵Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany
Background/Purpose: Ischemic complications such as digital ulcers (DU) are a common complication in systemic sclerosis (SSc) patients. The aim of this study was to combine…
Abstract Number: 2682 • 2017 ACR/ARHP Annual Meeting
Correlation between Capillaroscopic Patterns of Nailfold Microangiopathy and Three Different Methods to Assess Dermal Thickness in Systemic Sclerosis Patients
Barbara Ruaro¹, Alberto Sulli², Carmen Pizzorni¹, Elisa Alessandri¹, Sabrina Paolino¹, Massimo Ghio¹, Veronica Tomatis³, Vanessa Smith⁴ and Maurizio Cutolo¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino, Genoa, Italy, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, Genoa, Italy, ⁴Department of Rheumatology, Ghent University Hospital, Faculty of Internal Medicine, Ghent University, Ghent, Belgium, Ghent, Belgium
Background/Purpose: Systemic sclerosis (SSc) is characterized by increase of dermal thickness (DT) and impairment of microvascular system (1). Several studies demonstrate that nailfold capillaroscopy (NVC)…
Abstract Number: 3176 • 2016 ACR/ARHP Annual Meeting
Meta-Analysis of SSc Clinical Trials with Molecular Gene Expression Data Suggests Potential Combination Therapies
Jaclyn N. Taroni¹, Viktor Martyanov² and Michael L. Whitfield², ¹Department of Molecular & Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Clinical trials in SSc have tended to be underpowered and not meet clinical endpoints. Genome-wide gene expression measured in some studies can prove challenging…
Abstract Number: 844 • 2015 ACR/ARHP Annual Meeting
Identification of Subclinical Skin Involvement By High Frequency Ultrasound in Systemic Sclerosis Patients
Barbara Ruaro, Alberto Sulli, Elena Bernero, Marco A. Cimmino, Sabrina Paolino and Maurizio Cutolo, Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS A.O.U. San Martino-IST, University of Genova, Genoa, Italy, Genoa, Italy
Background/Purpose: Skin involvement may be evaluated in systemic sclerosis (SSc) by modified Rodnan skin score (mRSS), the validated method to distinguish between patients with limited…
Abstract Number: 2777 • 2014 ACR/ARHP Annual Meeting
Clinical-Biological Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data from a French Nationwide Study on 57 Patients
Marie Jachiet¹, Alain Le Quellec², Alban Deroux³, Pascal Godmer⁴, Mikael Ebbo⁵, Leonardo Astudillo⁶, Beatrice Flageul⁷, Nicolas Dupin⁸, Selim Aractingi¹, Loïc Guillevin for the French Vasculitis Study Group⁹, Luc Mouthon⁹ and Benjamin Terrier¹⁰, ¹Dermatology, Cochin Hospital, Paris, France, ²Division of internal Medicine, Hôpital Saint-Eloi, Centre Hospitalier Universitaire de Montpellier, Montpellier, Montpellier, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ⁵Internal Medicine, CHU, Marseille, France, ⁶Internal Medicine, CHU, Toulouse, France, ⁷Dermatology, Saint Louis, Paris, France, ⁸Service de Dermatologie, Hôpital Cochin, AP-HP, Paris, France, ⁹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹⁰National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose Hypocomplementemic urticarial vasculitis (HUV), an uncommon vasculitis of unknown etiology, is rarely reported. It is also called anti-C1q vasculitis in the 2012 revised International…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].